<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment trials for acute lymphoblastic leukemia in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment trials for acute lymphoblastic leukemia in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment trials for acute lymphoblastic leukemia in adults</div><div class="cntnt"><table cellspacing="0">
<tbody><tr>
<td class="subtitle1">Trial* (author, yr)</td>
<td class="subtitle1">n</td>
<td class="subtitle1">Age median (range), years</td>
<td class="subtitle1">Induction</td>
<td class="subtitle1">Consolidation</td>
<td class="subtitle1">Maintenance</td>
<td class="subtitle1">CNS-P</td>
<td class="subtitle1">CR, percent</td>
<td class="subtitle1">MRD, mos</td>
<td class="subtitle1">MS, mos</td>
<td class="subtitle1">DFS percent, yrs</td>
</tr>
<tr>
<td>GMALL 01 (Hoelzer 1988)</td>
<td>368</td>
<td>25 (15-65)</td>
<td>V, P, D, A, C, Ara- C, MP</td>
<td>V, Dex, Dox, C, Ara-C, TG</td>
<td>MP, MTX</td>
<td>IT MTX, XRT</td>
<td>74</td>
<td>24</td>
<td>28</td>
<td>35 (10)</td>
</tr>
<tr>
<td>SWOG L10M (Hussein 1989)</td>
<td>168</td>
<td>28 (15-85)</td>
<td>V, P, Dox, C</td>
<td>Ara-C, MTX, TG, V, P, A, C</td>
<td>V, P, Dox, MP, MTX, Dac, C, BCNU</td>
<td>IT MTX</td>
<td>68</td>
<td>23</td>
<td>18</td>
<td>NR</td>
</tr>
<tr>
<td>MDACC (Kantarjian 1990)</td>
<td>105</td>
<td>30</td>
<td>V, Dox, Dex ± C</td>
<td>MTX, A, Dox, Ara-C, V, P, ± allo HCT</td>
<td>MP, MTX, D, P</td>
<td> </td>
<td>84</td>
<td>22</td>
<td>19</td>
<td>34 (5)</td>
</tr>
<tr>
<td>UCSF (Linker 1991)</td>
<td>109</td>
<td>25 (16-49)</td>
<td>V, P, D, A</td>
<td>V, P, D, A, Ara-C, VM- 26, MTX</td>
<td>MP, MTX</td>
<td>IT MTX, XRT</td>
<td>88</td>
<td>NR</td>
<td>NR</td>
<td>35 (5)</td>
</tr>
<tr>
<td rowspan="2">ECOG 3486 (Cassileth 1992)</td>
<td>247</td>
<td>a) 35</td>
<td>a) V, P, D</td>
<td>HD Ara-C;</td>
<td>-</td>
<td>-</td>
<td>a) 73</td>
<td>NR</td>
<td>a) 9</td>
<td>a) 17 (2)</td>
</tr>
<tr>
<td> </td>
<td>b) 32</td>
<td>b) V, P, D, Ara-C, TG</td>
<td>MTX, A, C, Dox, V, P</td>
<td>-</td>
<td>-</td>
<td>b) 58</td>
<td>NR</td>
<td>b) 11</td>
<td>b) 35 (2)</td>
</tr>
<tr>
<td>LALA87 (Fiere 1993)</td>
<td>511</td>
<td>33</td>
<td>C, V, P, D or C, V, P, Z</td>
<td>Ara-C, A, with D or Z, allo-HCT or auto-HCT</td>
<td>V, P, MP, MTX, Dox, C, BCNU</td>
<td>IT MTX</td>
<td>76</td>
<td>17</td>
<td>18</td>
<td>chemo, 32 allo-HCT, 43 auto-HCT, 39</td>
</tr>
<tr>
<td>CALGB 8811 (Larson 1995)</td>
<td>197</td>
<td>32 (16-80)</td>
<td>V, P, D, A, C</td>
<td>C, Ara-C, MP, V, A, Dox, Dex, TG</td>
<td>V, P, MP, MTX</td>
<td>IT MTX, XRT</td>
<td>85</td>
<td>29</td>
<td>36</td>
<td>46 (3)</td>
</tr>
<tr>
<td>CALGB 9111 (Larson, 1998)</td>
<td>198</td>
<td>35 (16-83)</td>
<td>V, P, D, A, C</td>
<td>C, Ara-C, MP, V, A, Dox, Dex, TG</td>
<td>V, P, MP, MTX</td>
<td>IT MTX, XRT</td>
<td>85</td>
<td>NR</td>
<td>23</td>
<td>40 (3)</td>
</tr>
<tr>
<td>GIMEMA 0288 (Annino 2002)</td>
<td>778</td>
<td>28 (12-60)</td>
<td>V, P, D, A ± C</td>
<td>V, P, MIT, Dex, MTX, VM-26, Ara-C</td>
<td>V, P, MP, MTX</td>
<td>IT MTX</td>
<td>82</td>
<td>29</td>
<td>26</td>
<td>29 (9)</td>
</tr>
<tr>
<td>JALSG-ALL 93 (Takeuchi, 2002)</td>
<td>263</td>
<td>31 (15-59)</td>
<td>V, D, P, A, C</td>
<td>MIT, VP-16, Ara-C, MTX, aclarubicin, allo-HCT</td>
<td>MP, MTX</td>
<td>IT MTX, Ara-C, P</td>
<td>78</td>
<td>NR</td>
<td>NR</td>
<td>30 (5)</td>
</tr>
<tr>
<td>LALA94 (Thomas, 2004)</td>
<td>922</td>
<td>33 (18-79)</td>
<td>V, P, C, (D or I)</td>
<td><p>MIT + Ara-C or C, Ara-C, MP</p>
<p>In addition, high risk disease given allo-HCT or auto-HCT</p></td>
<td>MP, MTX, C, Ara-C, V, D, Dex</td>
<td>IT MTX, Ara-C, P ± XRT</td>
<td>84</td>
<td>NR</td>
<td>23</td>
<td><p>37 (3)</p>
<p>30 (5)</p></td>
</tr>
<tr>
<td>MD Anderson (Kantarjian, 2004)</td>
<td>288</td>
<td>40 (15-92)</td>
<td>C, V, D, Dex, MTX, Ara-C</td>
<td>C, V, D, Dex, MTX, Ara-C</td>
<td>MP, MTX, V, P</td>
<td>IT MTX</td>
<td>92</td>
<td>NR</td>
<td>32</td>
<td>NR</td>
</tr>
<tr>
<td>International trial ALL (Rowe, 2005)</td>
<td>1521</td>
<td>(15-59)</td>
<td>V, P, D, A</td>
<td>C, Ara-C, VP-16, MP, MTX, A, V, Dex, D, TG versus allo-HCT versus auto-HCT</td>
<td>V, P, MP, MTX</td>
<td>IT MTX, Ara-C, XRT</td>
<td>91</td>
<td>NR</td>
<td> <p>NR</p>
<p>Approx 20 mo</p></td>
<td><p>NR</p>
<p>OS 38 (5)</p></td>
</tr>
<tr>
<td>PETHEMA ALL-93 (Ribera, 2005)</td>
<td>222</td>
<td>27 (15-50)</td>
<td>V, D, P, A, C</td>
<td>V, Dex, MTX, C, Ara-C, A, MP, MIT, T, auto-HCT or allo-HCT</td>
<td>MP, MTX</td>
<td>IT MTX, Ara-C, HC</td>
<td>82</td>
<td>NR</td>
<td>23</td>
<td>35 (5)</td>
</tr>
<tr>
<td>GRAALL-2003 (Huguet, 2009)</td>
<td>225</td>
<td>31 (15-60)</td>
<td>V, P, D, A, C</td>
<td>Ara-C, Dex, A, MTX, V, MP, C, VP-16, P, D, I</td>
<td>V, P, MP, MTX</td>
<td>IT MTX, Ara-C, P, XRT</td>
<td>94</td>
<td>NR</td>
<td>NR</td>
<td>59 (3.5)</td>
</tr>
</tbody></table>
<!--[if gte mso 9]><xml>
<mso:CustomDocumentProperties>
<mso:Specialty msdt:dt="string">7.00000000000000</mso:Specialty>
<mso:Media_Type msdt:dt="string">Table</mso:Media_Type>
<mso:Edit_Table msdt:dt="string">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=26903&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>
</mso:CustomDocumentProperties>
</xml><![endif]-->
<title>Trials_of_ALL_in_adults.htm</title></div><div class="graphic_lgnd">This table shows results for various remission induction and postremission trials for acute lymphoblastic leukemia (ALL) in adults.</div><div class="graphic_footnotes">NR: not reported; CNS-P: CNS prophylaxis; XRT: cranial irradiation; CR: complete remission; MRD: median remission duration; MS: median survival; DFS: disease-free survival; C: cyclophosphamide; P: prednisone; MP: 6 mercaptopurine; VM-26: teniposide; Z: zorubicin; D: daunorubicin; HD Ara-C: high-dose cytarabine; MTX: methotrexate; Dac: dactinomycin; V: vincristine; Dox: Doxorubin; MIT: mitoxantrone; BCNU: carmustine; A: asparaginase; Dex: dexamethasone; TG: 6 thioguanine; IT MTX: intrathecal MTX; VP-16: etoposide; I: idarubicin; HC: hydrocortisone; T: teniposide; HCT: hematopoietic cell transplantation.<br/>* Trials with &gt;100 patients.</div><div id="graphicVersion">Graphic 61620 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
